Pancreatic cancer exhibits profound chemoresistance resulting either from pre-existing (intrinsic) mechanisms, or from anticancer drug treatment itself (acquired chemoresistance). To identify molecular alterations leading to acquired chemoresistance, the chemosensitive pancreatic carcinoma cell line PT45-P1 was exposed to low-dose treatment with etoposide for 6 weeks. Afterwards, these cells (PT45-P1res) were much more resistant to high-dose treatment with anticancer drugs than parental cells. Among several differentially expressed genes in PT45-P1res cells, IL-1b was most significantly upregulated, a finding in line with our previous observation that IL-1b accounts for intrinsic chemoresistance of pancreatic carcinoma cells. Elevated IL-1b expression in PT45-P1res cells was confirmed by real-time PCR and ELISA, and treatment with the IL-1 receptor antagonist restored drug-induced apoptosis. The increased IL-1b secretion was accompanied by an elevated formation of nitric oxide (NO) and a NO-dependent inhibition of the etoposide-induced caspase-3/-7/-8/-9 activity. Caspase activation was restored either by the iNOS inhibitor 1400W, the reducing agent dithiothreitol or the IL-1 receptor antagonist, resulting in greater sensitivity towards anticancer drug treatment. Conversely, IL-1b or the NO-donor SNAP decreased caspase activation and apoptosis in etoposide-treated PT45-P1 cells. These data confirm IL-1b and NO as determinants of chemoresistance in pancreatic cancer, and indicate that the intrinsic and acquired chemoresistance rely to some extent on common molecular targets beneficial for improved therapeutical strategies.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is 4-5th in the rank order of fatal malignant diseases in Western Countries, exhibiting a still increasing prevalence (Bramhal et al., 1995; Parker et al., 1997) . Owing to a highly malignant and progressive phenotype and a lack of specific symptoms, PDAC is diagnosed mostly at an already advanced state (Brand and Tempero, 1998; Lillemore, 1998 ) precluding a surgical intervention as the only curative option. For more than 85% of the patients, solely palliative options rely on radioor chemotherapy, both still with moderate success (Blaszkowsky, 1998; Neoptolemos et al., 2001) . This strong limitation of conventional treatment is mainly owing to the profound resistance of PDAC cells towards anti cancer drugs emerging from two distinct modes: (1) the intrinsic or innate chemoresistance, pre-existing before chemotherapeutic treatment, that is often induced by autocrine or paracrine mechanisms given by tumor-tumor or tumor-stroma interactions Mu¨erko¨ster et al., 2004) ; and (2) the acquired chemoresistance emerging during the course of chemotherapy (Banerjee et al., 2002; Kang et al., 2004 ).
An important way by which tumor cells gain protection from chemotherapeutic drugs is given by an altered balance of pro-and antiapoptotic proteins, along with a reduced apoptotic response (Morisaki and Katano, 2003; Soengas and Lowe, 2003) . In this context, the functional loss of the tumor-suppressor p53 (Brown and Attardi, 2005) , the upregulation of antiapoptotic molecules, for example, bcl-2, c-FLIP, XIAP (Medema et al., 1999; Kim et al., 2004; Yan et al., 2004) , or the downregulation of proapoptotic proteins, for example Smac/Diabolo and Bid (Erler et al., 2004; Yan et al., 2004) , have been extensively reported. Another important determinant of antiapoptotic protection in cancer cells, including PDAC, is the constitutive activation of the transcription factor NF-kB (Wang et al., 1999; Schmid and Adler, 2000) . Its inhibition significantly increases the sensitivity of PDAC cells towards chemotherapy in vitro and in vivo Mu¨erko¨ster et al., 2003) . Furthermore, we recently demonstrated that in various chemoresistant PDAC cells, the constitutive NF-kB activity relates to the autocrine action of IL-1b . This autocrine loop obviously evolves from tumor-stroma interactions, as shown for the chemosensitive PDAC cell lines PT45-P1 and T3M4 that, upon coculture with stromal fibroblasts, gained NF-kB-dependent chemoresistance preceeded by elevated IL-1b-secretion (Mu¨erko¨ster et al., 2004) . The importance of these factors in the development of innate chemoresistance was further supported by immunohistochemical stainings of human PDAC specimens, which revealed increased expression of the activated NF-kB subunit p65 and IL-1b in a large number of the tested tumor samples but not in normal pancreatic tissue (Mu¨erko¨ster et al., 2004; Mu¨erko¨ster et al., 2005) . As we have already described a model for the gain of innate chemoresistance in PT45-P1 cells emerging from tumor-stroma interactions, the aim of this study was to identify mechanisms underlying the acquired chemoresistance of this anti cancer-drug-sensitive cell line. For this purpose, PT45-P1 cells were treated over 6 weeks with a low dose of etoposide. Afterwards, these cells (PT45-P1res) together with the chemosensitive parental cell line were used for comparative analysis. The identification of molecular mechanisms accounting for both the innate and the acquired chemoresistance might offer common targets for the development of more efficient therapeutical strategies in the treatment of pancreatic carcinoma.
Results
Long-term cytotoxic drug treatment reduces chemosensitivity of PT45-P1 cells After treatment with a daily dose of 0. 2 mg/ml etoposide over 6 weeks (reflecting a course of chemotherapy), these long-term drug-treated PT45-P1 cells and their parental counterpart were both cultured under normal cell culture conditions for up to 10 weeks in order to perform further analyses. For detecting the induction of apoptosis after cytostatic drug treatment, both cell lines were either left untreated or exposed to 20 mg/ml etoposide or 5 mg/ml gemcitabine. After 24 h, cells were analysed for annexinV staining by flow cytometry. As shown in Figure 1a , treatment with etoposide induced significantly less apoptosis in long-term drug-treated PT45-P1 cells (therefore named PT45-P1res) than that in the parental cell line PT45-P1. Whereas 45% of PT45-P1 cells were apoptotic after cytostatic drug treatment, only 27% of the PT45-P1res cells showed an apoptotic phenotype indicated by annexinV staining. Similar results were obtained after treatment with gemcitabine ( Figure 1a ). In addition, the resistance towards treatment with TRAIL (2.5 mg/ml) and anti-CD95 (CH-11, 100 ng/ml), already existing in PT45-P1 cells was not significantly affected by the long-term etoposide exposure of PT45-P1res cells (Figure 1a) . To exclude that a reduced proliferation rate accounts for the reduced chemosensitivity in PT45-P1res cells, the cell cycle profile was analysed in PT45-P1 and PT45-P1res cells. Staining with the DNA intercalating dye propidium iodide (PI) revealed similar cell cycle profiles in chemosensitive PT45-P1 and in chemoresistant PT45-P1res cells (Figure 1b) . Correspondingly, the doubling times of both cell lines were nearly indistinguishable ( Figure 1c ). These results demonstrate that long-term drug exposure led to a stable chemoresistant phenotype of PT45-P1 cells. Furthermore, cellular mechanisms other than a reduced proliferation must account for this acquired chemoresistance.
Long-term drug treatment induces NF-kB and IL-1b secretion in PT45-P1res cells, accounting for chemoresistance As we have previously demonstrated that many PDAC cells show an enhanced NF-kB activation and elevated secretion of IL-1b, accounting for chemoresistance in vitro and in vivo Mu¨erko¨ster et al., 2004) , we paid particular attention here to these two factors. Interestingly, among several other differentially expressed genes, IL-1b was most significantly (more than fourfold) upregulated in PT45-P1res cells in comparison with PT45-P1 cells, as revealed by comparative cDNA-micorarray analysis of 409 different apoptosis-associated genes (data not shown). Real-time PCR (Figure 2a) and RT-PCR analysis (data not Figure 2b ). Furthermore, an ELISA detecting the activated NF-kB subunit p65 in nuclear extracts (Figure 2c ) as well as gelshift assays (data not shown) revealed that PT45-P1res cells showed significantly higher levels of activated NF-kB than PT45-P1 cells. This elevated basal NF-kB activity can be clearly reduced by the NF-kB inhibitor sulfasalazine (0.5 mmol/l) or the IL-1 receptor antagonist (IL1-RA, 250 ng/ml), which efficiently inhibits binding and signaling of IL-1b by binding to the IL-1 receptor. These results indicate an autocrine loop of constitutive NF-kB activation via the release of IL-1b as we already described for various chemoresistant PDAC cell lines as well as for T3M4 and PT45-P1 cells upon coculture with stromal fibroblasts (Mu¨erko¨ster et al., 2004) .
To verify IL-1b as a mediator of chemoresistance in PT45-P1res cells, the IL1-RA was used before treatment with cytotoxic drugs and apoptosis was determined by annexinV staining. Treatment with IL-1b and IL1-RA alone, respectively, did not affect the viability of either cell line (data not shown), whereas pretreatment with the IL1-RA increased the number of apoptotic PT45-P1res cells upon etoposide treatment from 27 to 66% (Figure 2d ), indicating that the elevated IL-1b expression contributes to the chemoresistant phenotype of PT45-P1res cells. Accordingly, administration of 20 ng/ml IL-1b significantly reduced the number of apoptotic PT45-P1 cells upon anticancer drug treatment from 46 to 28% (Figure 2d ), supporting the role of IL-1b in the mediation of chemoresistance in PDAC cells.
Decreased caspase activation in PT45-P1res cells is IL-1b dependent Next, we analysed the mechanisms of IL-1b-mediated chemoresistance in PT45-P1res cells in more detail. As it is known that the NF-kB target genes inhibitor of apoptosis proteins (IAPs) inhibit caspases and thereby account for apoptosis resistance (Friesen et al., 1999) , the expression levels of the most relevant caspases involved in apoptosis (the initiator caspases-8 and -9 and the effector caspases-3 and -7), as well as the expression of their endogenous inhibitors cIAP1/2 and XIAP were analysed by Western blotting. As shown in Figure 3a , PT45-P1 and PT45-P1res cells showed similar basal levels of all analysed procaspases (full-length form). In contrast, the appearance of cleaved caspases upon stimulation with etoposide, indicating activation of procaspases, was strongly attenuated in PT45-P1res cells compared to PT45-P1 cells. In addition, a homogeneous chemoluminiscent assay detecting the activity of the two downstream effector caspases-3 and -7 revealed a threefold reduced caspase-3/7 activity after etoposide treatment in PT45-P1res cells compared to PT45-P1 cells (Figure 3b ), thus confirming the Western blot data.
To verify whether increased expression of IAPs might account for the decreased caspase activation and Acquired chemoresistance in pancreatic cancer S Sebens Müerköster et al chemoresistance in PT45-P1res cells, expression analysis of cIAP1, cIAP2 and XIAP were performed by Western blotting. However, both cell lines showed similar expression levels of all three endogenous caspase inhibitors (Figure 3c ), as already indicated by the lack of distinct mRNA expression levels found with the DNA-microarray analysis. Thus, other mechanisms might be involved in the broad inhibition of caspase activation in PT45-P1res cells.
Next, we investigated whether the elevated IL-1b secretion accounts for the decreased caspase activation in PT45-P1res cells. Western blot analysis of PT45-P1res cell lysates revealed that administration of the IL1-RA enhanced etoposide-induced cleavage of the procaspases-3, -7, -8 and -9 (Figure 3a ) as compared to cells treated with etoposide alone, indicating that IL-1b attenuates anticancer-drug-dependent caspase activation in PT45-P1res cells. Moreover, IL-1b diminished cleavage of all four caspases after etoposide treatment in PT45-P1 cells (Figure 5a ). In support of this finding, the etoposide-induced caspase-3/7 activity increased in PT45-P1res cells when treated with the IL1-RA (Figure 3b ). As inhibition of IL-1b signaling increased also the number of annexinV-positive PT45-P1res cells after cytotoxic drug treatment (Figure 2d) , it can be concluded that the elevated IL-1b production and secretion results in a decreased caspase activation, thereby accounting for chemoresistance in PT45-P1res cells.
Drug-induced IL-1b enhances secretion of NO in PT45-P1res cells IL-1b is a known inducer of the inducible nitric oxide synthetase (iNOS) and production of nitric oxide (NO). Other reports demonstrated that inhibition of caspase activity might occur by S-nitrosylation of cysteine residues in the active site of the caspases (Li et al., 1997; Maejima et al., 2005) . In order to elucidate the mechanism of IL-1b-mediated caspase inhibition, we first analysed iNOS expression and NO secretion in PT45-P1 and PT45-P1res cells. In PT45-P1 cells, low levels of iNOS mRNA, strongly inducible by 20 ng/ml IL-1b within 3-6 h were detected by real-time PCR (Figure 4a ) and RT-PCR (data not shown). In contrast, PT45-P1res cells exhibited much higher iNOS mRNA levels that were reduced by the IL1-RA (Figure 4a ). Compared to PT45-P1 cells (2.1 mmol/10 5 cells), an elevated NO-release was found in untreated PT45-P1res cells (3.7 mmol/10 5 cells) and this secretion could be reduced by the IL1-RA (2.2 mmol/10 5 cells) (Figure 4b ). These data indicate that drug-induced IL-1b secretion leads to an increased NO release.
IL-1b-dependent NO secretion leads to decreased activation of caspases and chemoresistance of PT45-P1res cells To confirm whether the IL-1b-dependent NO secretion accounts for caspase inhibition, as seen in PT45-P1res cells, PT45-P1 cells were treated with IL-1b or without in the absence or presence of the specific iNOS inhibitor 1400W before etoposide administration, and PT45-P1res cells were treated with a combination of 1400W and etoposide for 48 h. Finally, caspase activation as well as apoptosis were analysed. Treatment with 10 mmol/l 1400W led to an efficient iNOS inhibition and significantly suppressed NO secretion: either that one in PT45-P1res cells endogenously induced in an IL-1b-dependent fashion or in PT45-P1 cells induced by exogenously administered IL-1b (data not shown). Along with iNOS inhibition, 1400W increased the etoposide-induced cleavage of the caspases-3, -7, -8 and -9 (Figure 5a ) as well as caspase-3/7 activity (Figure 5b ) in IL-1b-treated PT45-P1 cells and in PT45-P1res cells, as shown by Western blot analysis and caspase-3/7 assay, respectively. In PT45-P1 cells, IL-1b-diminished etoposide-induced caspase-3/7 activity from 4.4-to 2.8-fold, an effect that was completely abolished by 10 mmol/l 1400W (Figure 5b) , and in PT45-P1res cells, treatment with 1400W significantly increased etoposide-induced caspase-3/7 activity (from 2.1-to 4-fold). Furthermore, 
NO-induced caspase inhibition is abrogated under reducing conditions
To further elucidate the mechanism by which NO inhibits caspase activation, PT45-P1res cells were pretreated with 200 mmol/l of the reducing agent dithiothreitol (DTT), an established inhibitor of S-nitrosylation (Li et al., 1997; Kim et al., 2002) , to check whether etoposide-induced caspase activation and apoptosis could be increased. Furthermore, the NO-donor SNAP (200 mmol/l) was added in the absence or presence of DTT to PT45-P1 cells before etoposide treatment, and caspase activation as well as apoptosis were analysed. As shown by Western blot analysis and caspase-3/7 assay, SNAP reduced the amount of cleaved (activated) caspases-3, -7, -8 and -9 (Figure 6a ) as well as the activity of caspase-3/7 (Figure 6b ) in PT45-P1 cells subjected to etoposide treatment. This caspase-suppressive effect by SNAP was abolished by DTT. Accordingly, DTT treatment increased etoposide-induced cleavage of these four caspases in PT45-P1res cells (Figure 6a ), as well as the level of caspase-3/7 activity (Figure 6b) . AnnexinV staining revealed a reduced number of apoptotic PT45-P1 cells (27 versus 47%) in response to etoposide if SNAP was added before (Figure 6c) , indicating a NO-dependent gain of chemoresistance. Consequently, DTT abolished chemoresistance induced either by SNAP in PT45-P1 cells or by endogenous NO in PT45-P1res cells (Figure 6c ). These data demonstrate that NO, either derived from the NO-donor SNAP or from IL-1b-induced iNOS, suppresses caspase activation and activity in PT45-P1 cells most likely by S-nitrosylation, thereby confering chemoresistance.
Discussion
One major cause of the poor outcome of advanced pancreatic adenocarcinoma is the notoriously chemoresistant phenotype of PDAC cells precluding any curative option of conventional treatment. In order to improve current therapy, a better understanding is needed of how pancreatic carcinoma cells become chemoresistant, either by intrinsic mechanisms (innate chemoresistance), or by cytotoxic drug treatment itself (acquired chemoresistance). Our previous work using an in vitro coculture model demonstrated that the tumor microenvironment essentially contributes to the gain of innate chemoresistance in pancreatic cancer cells. We Acquired chemoresistance in pancreatic cancer S Sebens Müerköster et al could show that intense interactions of the tumor cells with surrounding stromal fibroblasts provide a mutual amplification loop of IL-1b and NO that confers chemoresistance (Mu¨erko¨ster et al., 2004) . The aim of this study was to elucidate the mechanisms leading to acquired chemoresistance of pancreatic carcinoma cells and to identify molecular targets in common with innate chemoresistance that might be of substantial benefit for improved therapeutical strategies. For this purpose, the PDAC cell line PT45-P1, already used in the in vitro coculture model, was exposed to a low dose of etoposide over 6 weeks, reflecting the exposure of tumor cells to a chemotherapy regimen. Although gemcitabine is currently the standard agent in the treatment of pancreatic cancer, the impact of this drug in terms of tumor remission and survival time is rather marginal. On the basis of our previous in vitro and in vivo studies demonstrating etoposide as a more effective drug in overcoming chemoresistance in various pancreatic cancer cells than gemcitabine Mu¨erko¨ster et al., 2003) , the former drug was mainly used throughout our experiments. PT45-P1 cells that passed through this treatment showed a stable chemoresistant phenotype and were termed PT45-P1res cells. Among several differentially expressed genes in these cells, IL-1b was most significantly upregulated as compared to the parental cell line, as identified by cDNA microarray analysis (not shown) and confirmed by real-time PCR and ELISA. We and others have previously demonstrated that IL-1b is an important determinant of chemoresistance in PDAC cells Mu¨erko¨ster et al., 2004) and in leukemia (Turzanski et al., 2004) or glioma cells (Poppenborg et al., 1999) as well. Consequently, inhibition of IL-1b signaling in these cells leads to the sensitization towards several cytostatic drugs. Reminiscent of the coculture model, after long-term exposure with etoposide, an IL-1b-dependent loop emerged also in PT45-P1res cells secreting elevated amounts of IL-1b on the one hand, and exhibiting upregulated iNOS expression and an elevated release of NO on the other hand. Thus, the innate as well as the acquired chemoresistance in PDAC cells are both characterized by these two cellular mediators. In addition, another common mediator closely related to IL-1b and NO is NF-kB, which is constitutively activated in the course of innate as well as acquired chemoresistance (Mu¨erko¨ster et al., 2004 (Mu¨erko¨ster et al., , 2005 .
Furthermore, we provide evidence for a mechanism by which constitutive IL-1b secretion contributes to chemoresistance in pancreatic carcinoma cells. IL-1b-induced NO leads to broad inhibition of caspases in PT45-P1res cells and hence, to a decreased sensitivity towards cytotoxic drug treatment. Apparently, this inhibition is caused by cystein S-nitrosylation of caspases as DTT (Li et al., 1997; Kim et al., 2002) reversed the NO-dependent caspase inhibition. As already shown for cardiomyocytes (Maejima et al., 2005) or hepatocytes (Li et al., 1997) , NO and the NO-derived species NO , ONOO À and NO þ can lead to S-nitrosylation of the cysteine residue in the active site of several caspases, such as caspase-1,-2, -3, -4, -6, -7 and -8. This redox modification of the caspases results in the inhibition of their proteolytic activation and a direct suppression of their activity (Jaiswal et al., 2001) . Indeed, while exhibiting similar expression levels of procaspase-3, -7, -8 and -9 compared to PT45-P1 cells, PT45-P1res cells displayed a strongly reduced etoposide-dependent cleavage and activity of these four caspases. The NOdependence of this effect was confirmed by our observation that the iNOS inhibitor 1400W abolished caspase inhibition and chemoresistance in PT45-P1res cells as well as in IL-1b treated PT45-P1 cells. Furthermore, treatment of PT45-P1 cells with the NO-donor SNAP (Stamler, 1994) resulted also in a blockade of druginduced caspase activation.
In support of the idea that direct S-nitrosylation of the caspases might account for the reduced caspase activation in PT45-P1res cells as well as in SNAPtreated PT45-P1 cells, the strong reducing agent DTT effectively reversed caspase inhibition and chemoresistance induced by SNAP in PT45-P1 cells or by endogenous NO in PT45-P1res cells. Of course, the mode of action by which NO causes chemoresistance in PDAC cells may not only rely on the direct modification of caspases but also on indirect alterations of the balance between cell survival and cell death (Kolb, 2000) . NO might induce the expression of antiapoptotic proteins such as heat-shock proteins via NF-kB activation, thereby providing antiapoptotic protection (Sreedhar and Csermely, 2004) . Furthermore, increased iNOS expression and NO levels might contribute to the stimulation of angiogenesis by inducing VEGF. This growth-stimulating mechanism together with the apoptosis-inhibiting effect thereby enhance the survival of genetically altered cells and promote carcinogenesis (Jaiswal et al., 2001) . Interestingly, the induction and manifestation of innate and acquired chemoresistance similarly involve a constitutive activation of NF-kB, an elevated release of IL-1b and an enhanced secretion of NO, thus underlining the important and common role of these signaling molecules in the gain of both modes of chemoresitance in pancreatic cancer. As NF-kB and IL-1b are both involved in the induction of iNOS and NO, these factors seem to be appropriate molecular structures that can be targeted to impair tumor progression and to increase chemosensitivity.
Materials and methods

Cell lines and culture
The human PDAC cell line PT45-P1 and its handling were described previously (Kalthoff et al., 1993) . PT45-P1 and PT45-P1res cells were cultured (371C, 5% CO 2 , 85% humidity) in RPMI40-medium (PAA-Laboratories, Co¨lbe, Germany) supplemented with 1% glutamine (Life Technologies, Eggenstein, Germany) and 10% FCS (Biochrom KG, Berlin, Germany). PT45-P1res cells were derived from PT45-P1 cells cultured in the presence of 0.2 mg/ml etoposide for 6 weeks, daily subjected to medium exchange and etoposide treatment. After etoposide treatment, cells were either stored in liquid PCR was performed with a MyiQ Single Color real-time PCR Detection System (BioRad). Data were collected during annealing steps and were further analysed using the i-Cycler iQ Optical system software (BioRad). All samples were analysed in duplicates and data are expressed as amount of mRNA in arbitrary units.
Statistics
Data are presented as mean7s.d. and analysed by Student's t-test. A P-value o0.05 (indicated as *in the figures) was considered as statistically significant.
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